All In Biotech

Drug Trial Radar · NCT01421186

A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma

A Phase 1/2a, Open-Label, Multicentre, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of the Human Anti-CD 38 Antibody MOR03087 as Monotherapy and in Combination With Standard Therapy in Subjects With Relapsed/Refractory Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Nov 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

91

Actual

Start

Jul 2011

Primary completion

Aug 2020

Study completion Aug 2020

Sponsor

Lead sponsor
MorphoSys AGIndustry
Sponsor type
Industry
First posted
Aug 22, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicentre, dose escalation study to characterize the safety and preliminary efficacy of the human anti-CD38 antibody MOR03087 (MOR202), in adult subjects with relapsed/refractory multiple myeloma, as monotherapy and in adult subjects with relapsed/refractory multiple myeloma in combination with standard therapy.

Conditions

  • Multiple Myeloma

Interventions

  • MOR03087 phase 1 dose escalationDrug

    Treatment cycles will be 28 days. Initial MOR03087 doses will be 0.01 mg/kg in part A, 4 mg/kg in parts B and C and 8 mg/kg in parts D and E; in all parts MOR03087 doses will be escalated to a maximum of 16 mg/kg. In part A, patients will receive a biweekly intravenous infusion of MOR03087 which will be administered on days 1 and 15 of the cycle. In parts B to E patients will receive a weekly intravenous infusion of MOR03087 which will be administered on days 1, 8, 15, and 22 of the cycle. In all parts a loading dose of MOR03087 will be additionally administered on day 4 of cycle 1.

  • MOR03087Drug

    MOR03087 will be administered according to the Maximum Tolerated Dose (MTD) or recommended dose and dosing regimen for MOR03087 from parts A-E of the phase I dose escalation. The biweekly MOR03087 regimen as described in part A; the weekly regimen as described for parts B-E.

  • DexamethasoneDrug

    Dexamethasone will be administered to patients orally; 40 mg (≤ 75 years old) or 20 mg (\> 75 years old) on days 1, 8, 15, and 22 of the 28-day cycle. An additional dose will be administered in cycle 1 on day 4.

  • PomalidomideDrug

    Pomalidomide will be administered to patients orally 4 mg on days 1-21 of the 28-day cycle.

  • LenalidomideDrug

    Lenalidomide will be administered to patients orally 25 mg on days 1-21 of the 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determination of Maximum Tolerated Dose and / or Recommended Dose and Dosing Regimen of MOR03087Time frame: First cycle of treatment
  2. Number of Participants Who Develop Anti-MOR03087 AntibodiesTime frame: during treatment period, maximum 3 years after 1st dose

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • AKH (Allgemeines Krankenhaus der Stadt Wien), Abteilung für Klinische Onkologie, Universitätsklinik für Innere Medizin I

    Vienna, Austria

  • Charité - Universitätsmedizin Berlin, CBF: Campus Benjamin Franklin, CC 14: Tumormedizin, Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie

    Berlin, Germany

  • Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus

    Dresden, Germany

  • Medizinische Klinik 5 - Hämatologie und Internist. Onkologie, Universitätsklinikum Erlangen

    Erlangen, Germany

  • Medizinische Universitätsklinik, Abt. Innere Medizin I

    Freiburg im Breisgau, Germany

  • Universitäsklinikum Heidelberg, Klin.-Pharmakologisches Studienzentrum

    Heidelberg, Germany

  • Sektion für Stammzell- und Immuntherapie, II. Medizinischen Klinik,

    Kiel, Germany

  • Klinikum rechts der Isar/ Studien / III. Med. Klinik

    Munich, Germany

  • Medizinische Klinik II, Abt. Hämatologie, Onkologie,

    Tübingen, Germany

  • Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Studienambulanz für Hämatologie/Onkologie und Infektiologie

    Würzburg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.